Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

301. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. (Abstract)

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed

1988 Lancet Controlled trial quality: uncertain

302. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. (Abstract)

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Two anticoagulant regimens, similar except for the timing of warfarin therapy, were compared in patients with clinically submassive venous thromboembolism (VTE). Warfarin was begun after 7 days of continuous intravenous heparin infusion in group L (127 patients) or within 3 days (average 1 day) of starting heparin in group S (139 patients), with similar outcomes. The frequency of symptomatic

1986 Lancet Controlled trial quality: uncertain

303. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. (Abstract)

Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. To compare the effects of heparin thrombolytic agents in pulmonary thromboembolic disease, we randomly assigned 40 patients with pulmonary emboli but without other clinical cardiopulmonary disease either to heparin followed by oral anticoagulants (21 patients) or to urokinse or streptokinase followed by heparin and then by oral anticoagulants (19 patients). The effects on pulmonary-capillary (...) blood volume and diffusing capacity were compared at two weeks and at one year. The pulmonary-capillary blood volume (in milliliters per square meter of body-surface area) was abnormally low (30 +/- 2.4) [+/- S.E.]; normal, 47 +/- 1.5) in the heparin-treated group at two weeks and remained unchanged at one year. In contrast, it was normal (45 +/- 2.5) in the group receiving thrombolytic agents, both at two weeks and at one year (P < 0.001). The pulmonary diffusing capacity was reduced to 69

1980 NEJM Controlled trial quality: uncertain

304. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. (Abstract)

Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised study comprising 1296 patients. 16 out of 653 patients in the placebo group had such complications within the treatment period of 1 week, compared with 4 out of 643 in the heparin group. This difference

1978 Lancet

305. Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. (Abstract)

Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. The results of a multicentre trial, designed to assess the efficacy of low-dose heparin in preventing fatal postoperative pulmonary embolism, were published in July 1975. In view of inconsistencies which have now become apparent in the data from one of the twenty-eight centres which took part in the trial, the results of the trial have been re-examined (...) , excluding the data from this centre. Of 4031 patients remaining after exclusion of these data, 2033 were in the control group and 1998 in the heparin group. 170 (4-2%) patients died during the postoperative period, 94 in the control group and 76 in the heparin group; 70-2% of deaths in the control group and 65-7% in the heparin group had necropsy examination. 15 patients in the control group and none in the heparin group were found at necropsy to have died due to acute massive fatal pulmonary embolism

1977 Lancet Controlled trial quality: uncertain

306. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. (Abstract)

Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. In a prospective controlled randomised trial, the prophylactic value of warfarin sodium (in doses aimed at maintaining a "Thrombotest" value of 10% and given from the day of admission until independent mobility had been achieved or for 3 mo, whichever was the sooner) was assessed in 160 elderly patients who had sustained a fracture of the femoral neck. Treatment significantly (...) reduced the frequency of deep venous thrombosis (D.V.T.), whether indicated by the 125I-fibrinogen test during life or assessed by detailed post-mortem studies. Pulmonary embolism was eliminated in treated patients, but the difference in mortality between the treatment and control groups was not significant, indicating that causes of death other than pulmonary embolism are of major importance in these elderly patients. A case is made out for prophylactic anticoagulation on a selective basis.

1976 Lancet

307. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. (Abstract)

Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. The efficacy of low-dose heparin in preventing fatal postoperative pulmonary embolism has been investigated in a multicentre prospective randomised trial. 4121 patients over the age of forty years undergoing a variety of elective major surgical procedures were included in the trial; 2076 of these were in the control group and 2045 patients received heparin. The two groups were well (...) matched for age, sex, weight, blood-group, and other factors which could predispose to the development of venous thromboembolism. 180 (4-4 %) patients died during the postoperative period, 100 in the control and 80 in the heparin group: 72% of deaths in the control and 66% in the heparin group had necropsy examination. 16 patients in the control group and 2 in the heparin group were found at necropsy to have died due to acute massive pulmonary embolism (P smaller than 0-005). In addition, emboli found

1975 Lancet Controlled trial quality: uncertain

308. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. (Abstract)

Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. 5536580 1971 01 15 2016 11 22 0098-7484 214 12 1970 Dec 21 JAMA JAMA Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. 2163-72 eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Fibrinolytic Agents 0 Serum Globulins 9001-32-5 Fibrinogen 9001-91-6 Plasminogen 9005-49-6 Heparin AIM IM Angiography Female Fibrinogen blood Fibrinolytic (...) Agents adverse effects therapeutic use Heart Failure complications Hematocrit Hemorrhage chemically induced Heparin adverse effects therapeutic use Humans Male Middle Aged Plasminogen blood Pulmonary Artery diagnostic imaging Pulmonary Embolism diagnosis drug therapy mortality Radionuclide Imaging Serum Globulins analysis Time Factors 1970 12 21 1970 12 21 0 1 1970 12 21 0 0 ppublish 5536580

1971 JAMA Controlled trial quality: predicted high